onartuzumab   

GtoPdb Ligand ID: 8966

Synonyms: MetMAb | OA-5D5 | OA5D5 | PRO 143966
Compound class: Antibody
Comment: Onartuzumab is an investigational, humanized monoclonal antibody targeting the MET receptor tyrosine kinase, a proto-oncogene which acts as a hepatocyte growth factor receptor. The protein is a monovalent (single-armed) construct, as opposed to bi-valent intact antibody structures.
Peptide sequence information for this antibody is available from its IMGT/mAb-DB record.
BLAST peptide analysis reveals identical match with sequences deposited with patent US7615529 [4], which relate to the monoclonal isolated from hybridoma 5D5.11.6 therein.
Bioactivity Comments
Patent US7615529 [4] does not provide an affinity value for the interaction between the antibody and its target [4]. We have tagged MET as the primary molecular target based on the information provided in this patent submission and have provided the IC50 value generated from a MET competitive binding assay with biotinylated HGF, reported in US20050227324 [2].
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
MET proto-oncogene, receptor tyrosine kinase Hs Antibody Binding 8.4 pIC50 - 2,4
pIC50 8.4 (IC50 4.3x10-9 M) [2,4]